Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

NCT01767194 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

73

Enrollment

NIH

Sponsor class

Conditions

Ganglioneuroblastoma
Recurrent Neuroblastoma

Interventions

BIOLOGICAL: Dinutuximab
DRUG: Irinotecan Hydrochloride
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Sargramostim
DRUG: Temozolomide
DRUG: Temsirolimus

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]